Sierra Oncology, Inc. (29)
Browse by Contract Category
Contracts
-
Loan and Security Agreement dated January 21, 2022 by and between the Company and Oxford Finance LLC
(Filed With SEC on May 6, 2022)
-
Form of Support Agreement, dated as of April 12, 2022, by and among GlaxoSmithKline plc, Orikum Acquisition Inc., Sierra Oncology, Inc, and certain securityholders of Sierra...
(Filed With SEC on April 13, 2022)
-
Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc, Orikum Acquisition Inc., and Sierra Oncology, Inc
(Filed With SEC on April 13, 2022)
-
Consulting Agreement dated March 22, 2022 between the Company and Mark Kowalski
(Filed With SEC on March 23, 2022)
-
License Agreement dated August 3, 2021 by and between the Registrant and AstraZeneca AB
(Filed With SEC on November 5, 2021)
-
Office Sublease, dated December 1, 2020, by and between Sierra Oncology Canada ULC and Scougall Management (1987) Limited and consented to on December 18, 2020 by Van885 West...
(Filed With SEC on March 11, 2021)
-
Transition Agreement and Release dated March 22, 2022 between the Company and Mark Kowalski
(Filed With SEC on March 23, 2022)
-
2018 Equity Inducement Plan, as amended, and forms of award agreements thereunder
(Filed With SEC on March 10, 2022)
-
Description of Securities
(Filed With SEC on March 10, 2022)
-
Form of Prefunded Warrant
(Filed With SEC on January 27, 2022)
-
Underwriting Agreement, dated as of January 26, 2022
(Filed With SEC on January 27, 2022)
-
Form of Amendment No. 1 to the Series B Warrant to Purchase Common Stock
(Filed With SEC on September 13, 2021)
-
Form of Amendment No. 1 to the Series A Warrant to Purchase Common Stock
(Filed With SEC on September 13, 2021)
-
Office Lease, dated December 10, 2020 and effective December 14, 2020, by and between Sierra Oncology, Inc. and KW Fund VI-San Mateo, LLC
(Filed With SEC on March 11, 2021)
-
Amendment No. 1 to the License Agreement dated November 10, 2020 by and between the Registrant and CRT Pioneer Fund LP
(Filed With SEC on March 11, 2021)
-
2018 Equity Inducement Plan, as amended, and forms of award agreements thereunder
(Filed With SEC on March 11, 2021)
-
2015 Equity Incentive Plan, as amended, and forms of award agreements thereunder
(Filed With SEC on March 11, 2021)
-
2018 Equity Inducement Plan, as amended, and forms of award agreements thereunder
(Filed With SEC on August 6, 2020)
-
Separation Agreement dated May 28, 2020 between the Registrant and Nick Glover
(Filed With SEC on August 6, 2020)
-
Form of Employment Agreement between the Registrant and Stephen G. Dilly
(Filed With SEC on August 6, 2020)
-
2015 Equity Incentive Plan, as amended, and forms of award agreements thereunder
(Filed With SEC on March 3, 2020)
-
Description of Securities
(Filed With SEC on March 3, 2020)
-
Amendment to Asset Purchase Agreement dated October 28, 2019, by and between the Registrant and YM Biosciences Australia Pty Ltd. and Gilead Sciences, Inc
(Filed With SEC on March 3, 2020)
-
Gilead Warrant, dated January 31, 2020
(Filed With SEC on February 6, 2020)
-
Securities Purchase Agreement, dated January 31, 2020, by and between the Company and Gilead Sciences, Inc
(Filed With SEC on February 6, 2020)
-
Form of Series A Convertible Voting Preferred Stock Certificate
(Filed With SEC on November 13, 2019)
-
Form of Series A Warrant
(Filed With SEC on November 7, 2019)
-
Form of Series B Warrant
(Filed With SEC on November 7, 2019)
-
Underwriting Agreement, dated November 7, 2019
(Filed With SEC on November 7, 2019)
